A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy.
Latest Information Update: 01 Dec 2023
At a glance
- Drugs Golimumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms GO-FORWARD
- Sponsors Centocor
- 01 Dec 2023 Results of post hoc pooled analysis from GO-BEFORE, GO-AFTER, and GO-FORWARD, GO-REVEAL and GO-RAISE assessing Long-term golimumab persistence, published in the Clinical Rheumatology
- 04 Jun 2022 Results assessing probability of GLM treatment retention over a 5-year period in adult patients with immune-mediated rheumatic diseases, by indication and line of therapy, using pooled data from five Phase III trials (GO-BEFORE, GO-AFTER and GO-FORWARD 3,8 ), PsA (GO-REVEAL), and AS (GO-RAISE)) presented at the 23rd Annual Congress of the European League Against Rheumatism.
- 05 Jun 2021 Results of a post hoc analysis assessing the patient-reported outcomes in RA patients from Asia treated with GLM in phase-3 trials (GO-FORWARD, NCT01248780) presented at the 22nd Annual Congress of the European League Against Rheumatism